flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 SGLT2 Inhibitors in the Management

In addition to problem-focused visits, we offer sports performance evaluations to stop problems before they start

(PubMed) Cantor AG, Bougatsos C, Dana T, Blazina I, McDonagh M

Limited Product Level Regulatory Review Compounded medications do not undergo FDA approval for finished products, unlike commercial drugs

Regular Follow-Up Scheduled visits and virtual check-ins help monitor your progress, answer questions, and make timely adjustments for your safety and satisfaction

The choice depends on your rebound risk (assessed via Precision Peptide Genetic Test), lifestyle preferences, and budget

Cardiovascular Health: Semaglutide extends beyond blood sugar control, offering potential cardiovascular benefits and reducing associated risks